🇺🇸 Placebo lanreotide in United States
3 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 3
Most-reported reactions
- Bile Duct Stenosis — 1 report (33.33%)
- Hepatic Failure — 1 report (33.33%)
- Sepsis — 1 report (33.33%)
Other Endocrinology approved in United States
Frequently asked questions
Is Placebo lanreotide approved in United States?
Placebo lanreotide does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Placebo lanreotide in United States?
University Hospital, Limoges is the originator. The local marketing authorisation holder may differ — check the official source linked above.